Mohammad Reza Haghshenas1, Nasrollah Erfani2,3, Sajjad Gerdabi4,5, Fatemeh Asadian6, Razie Kiani5, Bijan Khademi7. 1. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. haghshenasmr@sums.ac.ir. 2. Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. erfanin@sums.ac.ir. 3. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. erfanin@sums.ac.ir. 4. Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 6. Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 7. Department of Otolaryngology, Otolaryngology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
BACKGROUND: To investigate the differential expression of PD-1 and PD-L1 in salivary gland tumors (SGTs, malignant and benign subtypes) and determine their association with the clinicopathological characterization of the patients. METHODS: The immunohistochemistry was used to examine PD-1 and PD-L1 expression in specimens from 83 patients with primary SGTs including salivary ductal carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (ACC), mucoepidermoid carcinoma (MEC), warthin's tumors (WT), poleomorphic adenoma (PA) and other subtypes. RESULTS: The expression of PD-1 in peripheral and central immune cells (ICs) of MEC, and peripheral ICs of ACC was significantly higher than those with AdCC (P = 0.02, P = 0.02, P = 0.03, respectively). Interestingly, the expression of PD-1 was also observed in peripheral and central malignant tumor cells (TCs), particularly in SDC and ACC. Despite no significant difference in PD-L1 expression of TCs among malignant subtypes, the peripheral and central ICs of ACC and MEC were revealed to express PDL-1 significantly more than those with AdCC (P < 0.05). WTs were rich in PD-1/PD-L1 expressing ICs. However, the tumor microenvironment of PA generally had low levels of PD-1/PD-L1 expression. In general, the expression of PD-1 in peripheral and central TCs was found to be significantly higher in malignant tumors than in benign ones (P = 0.002 and P = 0.003, respectively). CONCLUSION: The simultaneous presentation of PD-1 and PD-L1 in TCs and ICs of SGTs, their significant association with disease severity as well as the positive correlation between these immune checkpoints may suggest the therapeutic potential of anti-PD-1 and anti-PDL-1 combinational immunotherapy for SGTs.
BACKGROUND: To investigate the differential expression of PD-1 and PD-L1 in salivary gland tumors (SGTs, malignant and benign subtypes) and determine their association with the clinicopathological characterization of the patients. METHODS: The immunohistochemistry was used to examine PD-1 and PD-L1 expression in specimens from 83 patients with primary SGTs including salivary ductal carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (ACC), mucoepidermoid carcinoma (MEC), warthin's tumors (WT), poleomorphic adenoma (PA) and other subtypes. RESULTS: The expression of PD-1 in peripheral and central immune cells (ICs) of MEC, and peripheral ICs of ACC was significantly higher than those with AdCC (P = 0.02, P = 0.02, P = 0.03, respectively). Interestingly, the expression of PD-1 was also observed in peripheral and central malignant tumor cells (TCs), particularly in SDC and ACC. Despite no significant difference in PD-L1 expression of TCs among malignant subtypes, the peripheral and central ICs of ACC and MEC were revealed to express PDL-1 significantly more than those with AdCC (P < 0.05). WTs were rich in PD-1/PD-L1 expressing ICs. However, the tumor microenvironment of PA generally had low levels of PD-1/PD-L1 expression. In general, the expression of PD-1 in peripheral and central TCs was found to be significantly higher in malignant tumors than in benign ones (P = 0.002 and P = 0.003, respectively). CONCLUSION: The simultaneous presentation of PD-1 and PD-L1 in TCs and ICs of SGTs, their significant association with disease severity as well as the positive correlation between these immune checkpoints may suggest the therapeutic potential of anti-PD-1 and anti-PDL-1 combinational immunotherapy for SGTs.
Authors: Arya Amini; Timothy V Waxweiler; Jeffrey V Brower; Bernard L Jones; Jessica D McDermott; David Raben; Debashis Ghosh; Daniel W Bowles; Sana D Karam Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-11-01 Impact factor: 6.223
Authors: Pawel Sowa; Karolina Goroszkiewicz; Joanna Szydelko; Joanna Chechlinska; Katarzyna Pluta; Wojciech Domka; Maciej Misiolek; Wojciech Scierski Journal: Biomed Res Int Date: 2018-08-01 Impact factor: 3.411
Authors: Michał Żurek; Anna Rzepakowska; Kamil Jasak; Kazimierz Niemczyk Journal: Int J Environ Res Public Health Date: 2021-12-24 Impact factor: 3.390
Authors: Shumei Kato; Sheryl K Elkin; Maria Schwaederle; Brett N Tomson; Teresa Helsten; Jennifer L Carter; Razelle Kurzrock Journal: Oncotarget Date: 2015-09-22
Authors: J S Ross; L M Gay; K Wang; J A Vergilio; J Suh; S Ramkissoon; H Somerset; J M Johnson; J Russell; S Ali; A B Schrock; D Fabrizio; G Frampton; V Miller; P J Stephens; J A Elvin; D W Bowles Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976